Form 4 for QURE uniQure N.V.
Accepted 2026-07-07 16:47:25 ET · period of report 2026-07-02 · accession 0000904454-26-000397 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-07 16:47 | 2026-07-02 | QURE | Kapusta Matthew C | CEO, Managing Dir, Dir | M - OptEx | $19.39 | +21.1K | 540.3K | +4% | +$408.8K |
| DMT | 2026-07-07 16:47 | 2026-07-02 | QURE | Kapusta Matthew C | CEO, Managing Dir, Dir | S - Sale+OE | $45.16 | -21.1K | 519.2K | -4% | -$952.1K |
| DT | 2026-07-07 16:47 | 2026-07-02 | QURE | Kapusta Matthew C | CEO, Managing Dir, Dir | M - OptEx | $0.00 | -21.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-07-02 | M | A | 21,082 | $19.39 | 540,309 | D | — | — | (F1) The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. |
| 2 | Common | Ordinary Shares | 2026-07-02 | S | D | 9,200 | $44.43 | 531,109 | D | — | — | (F1) The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.10 to $44.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Ordinary Shares | 2026-07-02 | S | D | 4,282 | $45.43 | 526,827 | D | — | — | (F1) The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.95. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Ordinary Shares | 2026-07-02 | S | D | 7,600 | $45.89 | 519,227 | D | — | — | (F1) The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. (F4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.48 to $46.10. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-07-02 | M | D | 21,082 | $0.00 | 0 | D | $19.39 · — to 2028-01-26 | 21,082 Ordinary Shares | (F1) The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. (F5) The Stock Option vested in full on January 26, 2022. |